Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 71Prostatic Neoplasms 67Neoplasm Metastasis 56Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 45Multiple Myeloma 44Colorectal Neoplasms 41Pancreatic Neoplasms 37Myelodysplastic Syndromes 35Carcinoma, Renal Cell 33Ovarian Neoplasms 31Melanoma 31Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Glioblastoma 27Triple Negative Breast Neoplasms 26Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 24Lymphoma 23Burkitt Lymphoma 22Squamous Cell Carcinoma of Head and Neck 21Glioma 20Fallopian Tube Neoplasms 20Carcinoma, Hepatocellular 18Mouth Neoplasms 17Leukemia, Biphenotypic, Acute 17Brain Neoplasms 17Sarcoma 16Oropharyngeal Neoplasms 16

Interventions

Magnetic Resonance Spectroscopy 16Hydroxyurea 7Everolimus 7Bevacizumab 7lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6Proton Therapy 6Specimen Handling 5pembrolizumab 4Surgical Procedures, Operative 4Radiosurgery 4Imatinib Mesylate 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4aldesleukin 3abemaciclib 3Tranexamic Acid 3Temozolomide 3Sunitinib 3Sodium Chloride 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Nivolumab 3Ga(III)-DOTATOC 390Y-octreotide, DOTA-Tyr(3)- 3vistusertib 2trametinib 2ribociclib 2fludarabine 2arginyllysine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Meningioma × Specimen Handling × Clear all
NCT07150806 2026-05-22

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
30 enrolled
CNS

Meningioma

NCT03604978 2026-05-13

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
38 enrolled
CNS

Meningioma

NCT03180268 2026-05-07

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

NRG Oncology

Phase 3 Recruiting
163 enrolled
CNS

Meningioma

NCT04082520 2026-04-22

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Mayo Clinic

Phase 2 Recruiting
42 enrolled
CNS

Meningioma

NCT06132685 2026-02-10

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

Emory University

Phase 2 Recruiting
200 enrolled
CNS

Brain Neoplasms, Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡